Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    10673079 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
Conditions: Cirrhosis;   Ascites;   Nosocomial Spontaneous Bacterial Peritonitis
Interventions: Drug: Daptomycin + Meropenem;   Drug: Ceftazidime

Indicates status has not been verified in more than two years